[go: up one dir, main page]

CL2008001469A1 - Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros. - Google Patents

Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros.

Info

Publication number
CL2008001469A1
CL2008001469A1 CL2008001469A CL2008001469A CL2008001469A1 CL 2008001469 A1 CL2008001469 A1 CL 2008001469A1 CL 2008001469 A CL2008001469 A CL 2008001469A CL 2008001469 A CL2008001469 A CL 2008001469A CL 2008001469 A1 CL2008001469 A1 CL 2008001469A1
Authority
CL
Chile
Prior art keywords
triazole
bithenyl
amikacin
tobramycin
ciprofloxacin
Prior art date
Application number
CL2008001469A
Other languages
English (en)
Inventor
David Reid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008001469A1 publication Critical patent/CL2008001469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de compuestos derivados de triazol para preparar un medicamento para tratar la formación de biopelículas por la bacteria pseudomonas aeruginosa en los pulmones.
CL2008001469A 2007-05-22 2008-05-20 Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros. CL2008001469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108650A EP1994930A1 (en) 2007-05-22 2007-05-22 Triazol compounds for treating biofilm formation

Publications (1)

Publication Number Publication Date
CL2008001469A1 true CL2008001469A1 (es) 2010-10-29

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001469A CL2008001469A1 (es) 2007-05-22 2008-05-20 Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros.

Country Status (18)

Country Link
US (2) US8309590B2 (es)
EP (3) EP1994930A1 (es)
JP (1) JP5470245B2 (es)
KR (1) KR101519675B1 (es)
CN (2) CN103381271A (es)
AU (1) AU2008252964B2 (es)
BR (1) BRPI0811103A2 (es)
CA (1) CA2685112A1 (es)
CL (1) CL2008001469A1 (es)
IL (1) IL201832A (es)
MA (1) MA31388B1 (es)
MX (1) MX2009012628A (es)
NZ (1) NZ580735A (es)
RU (1) RU2478385C2 (es)
TN (1) TN2009000487A1 (es)
TW (1) TWI419690B (es)
WO (1) WO2008142094A1 (es)
ZA (1) ZA200907415B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
WO2001070213A2 (en) 2000-03-23 2001-09-27 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7498292B2 (en) 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation

Also Published As

Publication number Publication date
TN2009000487A1 (en) 2011-03-31
RU2009147297A (ru) 2011-06-27
MX2009012628A (es) 2009-12-07
JP5470245B2 (ja) 2014-04-16
US20100152101A1 (en) 2010-06-17
EP2253317A2 (en) 2010-11-24
AU2008252964A1 (en) 2008-11-27
KR101519675B1 (ko) 2015-05-12
BRPI0811103A2 (pt) 2014-12-09
NZ580735A (en) 2012-02-24
US8309590B2 (en) 2012-11-13
KR20100017153A (ko) 2010-02-16
JP2010527960A (ja) 2010-08-19
CN101678004A (zh) 2010-03-24
ZA200907415B (en) 2010-07-28
US8592473B2 (en) 2013-11-26
MA31388B1 (fr) 2010-05-03
EP1994930A1 (en) 2008-11-26
IL201832A0 (en) 2010-06-16
RU2478385C2 (ru) 2013-04-10
AU2008252964B2 (en) 2011-12-01
IL201832A (en) 2015-11-30
WO2008142094A1 (en) 2008-11-27
TWI419690B (zh) 2013-12-21
TW200913996A (en) 2009-04-01
EP2162130A1 (en) 2010-03-17
EP2253317A3 (en) 2011-03-16
CN103381271A (zh) 2013-11-06
WO2008142094A4 (en) 2009-01-29
CA2685112A1 (en) 2008-11-27
US20120329746A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
CL2008001469A1 (es) Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros.
BRPI0813450B8 (pt) composto, formulação farmacêutica, e, usos do composto
ES2523968T3 (es) Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
BRPI0307267B8 (pt) uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
ECSP077182A (es) Metodos para el tratamiento de infecciones endobronquiales
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
NO20083250L (no) Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
BRPI0405939A (pt) Formulações antibacterianas de uso tópico
ATE528311T1 (de) Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
DOP2006000268A (es) Agentes antibacterianos
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
GT200600160A (es) Tratamiento del dolor
CL2009001395A1 (es) Composición fungicida y bactericida biológica, libre de antibioticos que comprende brevibacillus parabrevis nrrl b50390, bacillus subtilis nrrl b50391, bacillus cereus nrrl b50392 y bacillus cereus nrrl b50393; método de tratamiento antifúngico y/o bactericida de plantas; y mezcla bactericida y fungicida.
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
CL2023002933A1 (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
CR9691A (es) Inhibidores de 6-alquilideno-peneme b-lactama biciclicos y combinacion antibiotica de b-lactama: un antibiotico de amplio espectro